Rubius Therapeutics Inc. buy me8
Start price
14.12.20
/
50%
€8.20
Target price
14.12.21
€11.00
Performance (%)
15.85%
End price
29.01.21
€9.50
Summary
This prediction ended on 29.01.21 with a price of €9.50. The BUY prediction by me8 finished with a performance of 15.85%. me8 has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Rubius Therapeutics Inc. | - | - | - | - |
iShares Core DAX® | 1.937% | 1.473% | 18.596% | 15.757% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% | 35.363% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% | 10.532% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% | 36.692% |
According to me8 what are the pros and cons of Rubius Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Very capable Management
Good culture
Top 10 in its market
Cons
Sustainability is little important
Higher risks for its business
Comments by me8 for this prediction
In the thread Rubius Therapeutics Inc. diskutieren
Buy mit Kursziel 11,0
In the thread Trading Rubius Therapeutics Inc.
Buy beendet
Stopped prediction by me8 for Rubius Therapeutics Inc.
Rubius Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.14
04.09.22
04.09.22
-
04.09.23
04.09.23
-92.50%
05.09.23
05.09.23
Could be worthwhile Investment >10% per year
Very capable Management
Good culture
Sustainability is little important